Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ovid Therapeutics Inc
(NQ:
OVID
)
3.150
-0.125 (-3.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ovid Therapeutics Inc
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
May 14, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
March 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
December 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
November 03, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
October 10, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
September 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
August 30, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
August 04, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
June 28, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Added to Russell 3000® Index
June 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 05, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
May 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
April 27, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
March 09, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
March 08, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
February 28, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
February 08, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
January 05, 2023
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
December 02, 2022
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 08, 2022
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.